nach oben

Erschienen in:

20.02.2020 | Schwerpunkt

Darm-Herz-Achse

Wie Darmbakterien kardiovaskuläre Erkrankungen beeinflussen

verfasst von: Hendrik Bartolomaeus, Victoria McParland, Dr. med. Nicola Wilck

Erschienen in: Herz | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Betrachtung des Menschen als einen Holobionten, bestehend aus eukaryotischen Wirtszellen und assoziierten prokaryotischen Lebewesen, hat eine neue Perspektive auf die kardiovaskuläre Pathophysiologie eröffnet. Insbesondere die Bakterien des Darms beeinflussen die Zell- und Organfunktionen ihres Wirts. Darmbakterien stellen eine stoffwechselaktive Gemeinschaft dar, deren Zusammensetzung und Funktion kardiovaskuläre Erkrankungen beeinflussen kann. Die Interaktion zwischen Darmbakterien und Herz erfolgt über Metabolite bakteriellen Ursprungs, welche im Darm resorbiert und über die Zirkulation verteilt werden. Bakterielle Metabolite entstehen aus Nahrungsbestandteilen, was wiederum die Bedeutung der Ernährung unterstreicht. Manche dieser Metabolite, wie z. B. Trimethylamin-N-oxid (TMAO), können kardiovaskuläre Pathologien verstärken. Kurzkettige Fettsäuren wiederum werden als protektive Metabolite betrachtet. Das Immunsystem des Wirts ist dabei ein wichtiger Angriffspunkt für diese Metabolite und erklärt einen großen Teil ihrer Wirkungen. In der Zukunft könnte die gezielte Beeinflussung der Darmbakterien helfen, die Entstehung und Progression von kardiovaskulären Erkrankungen zu verhindern.

Morgan XC, Huttenhower C (2012) Chapter 12: human microbiome analysis. PLoS Comput Biol 8:e1002808. https://doi.org/10.1371/journal.pcbi.1002808 CrossRefPubMedPubMedCentral

Sender R, Fuchs S, Milo R (2016) Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 14:e1002533. https://doi.org/10.1371/journal.pbio.1002533 CrossRefPubMedPubMedCentral

Tierney BT et al (2019) The landscape of genetic content in the gut and oral human microbiome. Cell Host Microbe 26:283–295.e8. https://doi.org/10.1016/j.chom.2019.07.008 CrossRefPubMedPubMedCentral

Nishida A et al (2018) Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol 11:1–10. https://doi.org/10.1007/s12328-017-0813-5 CrossRefPubMed

Castellarin M et al (2012) Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 22:299–306. https://doi.org/10.1101/gr.126516.111 CrossRefPubMedPubMedCentral

Ley RE, Turnbaugh PJ, Klein S, Gordon JI (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444:1022–1023. https://doi.org/10.1038/4441022a CrossRefPubMed

Karlsson FH et al (2013) Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498:99–103. https://doi.org/10.1038/nature12198 CrossRefPubMed

Qin J et al (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:55–60. https://doi.org/10.1038/nature11450 CrossRefPubMed

Vaziri ND et al (2013) Chronic kidney disease alters intestinal microbial flora. Kidney Int 83:308–315. https://doi.org/10.1038/ki.2012.345 CrossRefPubMed

10.

Yang T et al (2015) Gut dysbiosis is linked to hypertension. Hypertension 65:1331–1340. https://doi.org/10.1161/HYPERTENSIONAHA.115.05315 CrossRefPubMed

11.

Karlsson FH et al (2012) Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun 3:1245. https://doi.org/10.1038/ncomms2266 CrossRefPubMed

12.

Zhu Q et al (2018) Dysbiosis signatures of gut microbiota in coronary artery disease. Physiol Genomics 50:893–903. https://doi.org/10.1152/physiolgenomics.00070.2018 CrossRefPubMed

13.

Cui X et al (2018) Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. Sci Rep 8:635. https://doi.org/10.1038/s41598-017-18756-2 CrossRefPubMedPubMedCentral

14.

Forslund K et al (2015) Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528:262–266. https://doi.org/10.1038/nature15766 CrossRefPubMedPubMedCentral

15.

Rothschild D et al (2018) Environment dominates over host genetics in shaping human gut microbiota. Nature 555:210–215. https://doi.org/10.1038/nature25973 CrossRefPubMed

16.

Zhernakova A et al (2016) Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352:565–569. https://doi.org/10.1126/science.aad3369 CrossRefPubMedPubMedCentral

17.

Williams B et al (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104. https://doi.org/10.1093/eurheartj/ehy339 CrossRefPubMed

18.

Knuuti J et al (2019) ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. https://doi.org/10.1093/eurheartj/ehz425 CrossRefPubMed

19.

Ridker PM et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131. https://doi.org/10.1056/NEJMoa1707914 CrossRefPubMed

20.

Sandek A et al (2012) Studies on bacterial endotoxin and intestinal absorption function in patientswith chronic heart failure. Int J Cardiol 157:80–85. https://doi.org/10.1016/j.ijcard.2010.12.016 CrossRefPubMed

21.

Kim S et al (2018) Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clin Sci 132:701–718. https://doi.org/10.1042/CS20180087 CrossRef

22.

Thaiss CA et al (2018) Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science 359:1376–1383. https://doi.org/10.1126/science.aar3318 CrossRefPubMed

23.

Vaziri ND et al (2012) Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transplant 27:2686–2693. https://doi.org/10.1093/ndt/gfr624 CrossRefPubMed

24.

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305. https://doi.org/10.1056/NEJMoa041031 CrossRefPubMed

25.

Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR (2006) Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 72:384–393. https://doi.org/10.1016/j.cardiores.2006.09.011 CrossRefPubMed

26.

Sabico S et al (2019) Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: a randomized, double-blind, placebo-controlled trial. Clin Nutr 38:1561–1569. https://doi.org/10.1016/j.clnu.2018.08.009 CrossRefPubMed

27.

Wang IK et al (2015) The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Beneficial Microbes 6:423–430. https://doi.org/10.3920/BM2014.0088 CrossRefPubMed

28.

Collaborators GBDD (2019) Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 393:1958–1972. https://doi.org/10.1016/S0140-6736(19)30041-8 CrossRef

29.

Miranda PM et al (2018) High salt diet exacerbates colitis in mice by decreasing Lactobacillus levels and butyrate production. Microbiome 6:57. https://doi.org/10.1186/s40168-018-0433-4 CrossRefPubMedPubMedCentral

30.

Wang C et al (2017) High-salt diet has a certain impact on protein digestion and gut Microbiota: a sequencing and Proteome combined study. Front Microbiol 1838:8. https://doi.org/10.3389/fmicb.2017.01838 CrossRef

31.

Wilck N et al (2017) Salt-responsive gut commensal modulates TH17 axis and disease. Nature 551:585–589. https://doi.org/10.1038/nature24628 CrossRefPubMedPubMedCentral

32.

Nguyen H et al (2013) Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovasc Res 97:696–704. https://doi.org/10.1093/cvr/cvs422 CrossRefPubMed

33.

Norlander AE et al (2016) Interleukin-17A regulates renal sodium transporters and renal injury in angiotensin II-induced hypertension. Hypertension 68:167–174. https://doi.org/10.1161/HYPERTENSIONAHA.116.07493 CrossRefPubMed

34.

Gutierrez-Vazquez C, Quintana FJ (2018) Regulation of the immune response by the arylhydrocarbon receptor. Immunity 48:19–33. https://doi.org/10.1016/j.immuni.2017.12.012 CrossRefPubMedPubMedCentral

35.

Zelante T et al (2013) Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39:372–385. https://doi.org/10.1016/j.immuni.2013.08.003 CrossRefPubMed

36.

Hung SC, Kuo KL, Wu CC, Tarng DC (2017) Indoxyl sulfate: a novel cardiovascular risk factor in chronic kidney disease. JAHA. https://doi.org/10.1161/JAHA.116.005022 CrossRefPubMedPubMedCentral

37.

Nakano T et al (2019) Uremic toxin indoxyl sulfate promotes proinflammatory macrophage activation via the interplay of OATP2B1 and Dll4-notch signaling. Circulation 139:78–96. https://doi.org/10.1161/CIRCULATIONAHA.118.034588 CrossRefPubMedPubMedCentral

38.

Devlin AS et al (2016) Modulation of a circulating uremic solute via rational genetic manipulation of the Gut microbiota. Cell Host Microbe 20:709–715. https://doi.org/10.1016/j.chom.2016.10.021 CrossRefPubMedPubMedCentral

39.

Pietinen P et al (1996) Intake of dietary fiber and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Circulation 94:2720–2727. https://doi.org/10.1161/01.cir.94.11.2720 CrossRefPubMed

40.

McLoughlin RF, Berthon BS, Jensen ME, Baines KJ, Wood LG (2017) Short-chain fatty acids, prebiotics, synbiotics, and systemic inflammation: a systematic review and meta-analysis. Am J Clin Nutr 106:930–945. https://doi.org/10.3945/ajcn.117.156265 CrossRefPubMed

41.

Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT (1987) Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28:1221–1227CrossRefPubMedPubMedCentral

42.

Brestoff JR, Artis D (2013) Commensal bacteria at the interface of host metabolism and the immune system. Nat Immunol 14:676–684. https://doi.org/10.1038/ni.2640 CrossRefPubMedPubMedCentral

43.

Morrison DJ, Preston T (2016) Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 7:189–200. https://doi.org/10.1080/19490976.2015.1134082 CrossRefPubMedPubMedCentral

44.

Pluznick JL et al (2013) Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci USA 110:4410–4415. https://doi.org/10.1073/pnas.1215927110 CrossRefPubMedPubMedCentral

45.

Nicholson JK et al (2012) Host-gut microbiota metabolic interactions. Science 336:1262–1267. https://doi.org/10.1126/science.1223813 CrossRefPubMed

46.

Fleming SE, Fitch MD, DeVries S, Liu ML, Kight C (1991) Nutrient utilization by cells isolated from rat jejunum, cecum and colon. J Nutr 121:869–878. https://doi.org/10.1093/jn/121.6.869 CrossRefPubMed

47.

Wang HB, Wang PY, Wang X, Wan YL, Liu YC (2012) Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin‑1 transcription. Dig Dis Sci 57:3126–3135. https://doi.org/10.1007/s10620-012-2259-4 CrossRefPubMed

48.

Natarajan N et al (2016) Microbial short chain fatty acid metabolites lower blood pressure via endothelial G protein-coupled receptor 41. Physiological Genomics 48:826–834. https://doi.org/10.1152/physiolgenomics.00089.2016 CrossRefPubMedPubMedCentral

49.

Bartolomaeus H et al (2019) Short-chain fatty acid propionate protects from hypertensive cardiovascular damage. Circulation 139:1407–1421. https://doi.org/10.1161/CIRCULATIONAHA.118.036652 CrossRefPubMed

50.

Marques FZ et al (2017) High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation 135:964–977. https://doi.org/10.1161/CIRCULATIONAHA.116.024545 CrossRefPubMed

51.

Arpaia N et al (2013) Metabolites produced by commensal bacteria promote peripheral regulatory T‑cell generation. Nature. https://doi.org/10.1038/nature12726 CrossRefPubMedPubMedCentral

52.

Furusawa Y et al (2013) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. https://doi.org/10.1038/nature12721 CrossRefPubMed

53.

Kasahara K et al (2018) Interactions between Roseburia intestinalis and diet modulate atherogenesis in a murine model. Nat Microbiol 3:1461–1471. https://doi.org/10.1038/s41564-018-0272-x CrossRefPubMedPubMedCentral

54.

Li J, Lin S, Vanhoutte PM, Woo CW, Xu A (2016) Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in apoe−/− mice. Circulation 133:2434–2446. https://doi.org/10.1161/CIRCULATIONAHA.115.019645 CrossRefPubMed

55.

Rault-Nania MH et al (2006) Inulin attenuates atherosclerosis in apolipoprotein E‑deficient mice. Br J Nutr 96:840–844. https://doi.org/10.1017/bjn20061913 CrossRefPubMed

56.

Brandsma E et al (2019) A Proinflammatory gut microbiota increases systemic inflammation and accelerates atherosclerosis. Circ Res 124:94–100. https://doi.org/10.1161/CIRCRESAHA.118.313234 CrossRefPubMed

57.

Guasch-Ferre M et al (2019) meta-analysis of randomized controlled trials of red meat consumption in comparison with various comparison diets on cardiovascular risk factors. Circulation 139:1828–1845. https://doi.org/10.1161/CIRCULATIONAHA.118.035225 CrossRefPubMed

58.

Tang WHW, Li DY, Hazen SL (2019) Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol 16:137–154. https://doi.org/10.1038/s41569-018-0108-7 CrossRefPubMedPubMedCentral

59.

Wang Z et al (2011) Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472:57–63. https://doi.org/10.1038/nature09922 CrossRefPubMedPubMedCentral

60.

Koeth RA et al (2013) Intestinal microbiota metabolism of l‑carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19:576–585. https://doi.org/10.1038/nm.3145 CrossRefPubMedPubMedCentral

61.

Al-Waiz M, Mitchell SC, Idle JR, Smith RL (1987) The metabolism of 14C-labelled trimethylamine and its N‑oxide in man. Xenobiotica 17:551–558. https://doi.org/10.3109/00498258709043962 CrossRefPubMed

62.

Hai X et al (2015) Mechanism of Prominent Trimethylamine Oxide (TMAO) Accumulation in Hemodialysis Patients. PLoS ONE 10:e143731. https://doi.org/10.1371/journal.pone.0143731 CrossRefPubMedPubMedCentral

63.

Tang WH et al (2015) Gut microbiota-dependent trimethylamine N‑oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 116:448–455. https://doi.org/10.1161/CIRCRESAHA.116.305360 CrossRefPubMed

64.

Mente A et al (2015) The relationship between trimethylamine-N-oxide and prevalent cardiovascular disease in a multiethnic population living in Canada. Can J Cardiol 31:1189–1194. https://doi.org/10.1016/j.cjca .2015.06.016CrossRefPubMed

65.

Tang WH et al (2013) Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 368:1575–1584. https://doi.org/10.1056/NEJMoa1109400 CrossRefPubMedPubMedCentral

66.

Tang WH et al (2014) Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol 64:1908–1914. https://doi.org/10.1016/j.jacc.2014.02.617 CrossRefPubMed

67.

Gruppen EG et al (2017) TMAO is Associated with Mortality: Impact of Modestly Impaired Renal Function. Sci Rep 7:13781. https://doi.org/10.1038/s41598-017-13739-9 CrossRefPubMedPubMedCentral

68.

Meyer KA et al (2016) Microbiota-dependent metabolite trimethylamine N‑oxide and coronary artery calcium in the coronary artery risk development in young adults study (CARDIA). JAHA. https://doi.org/10.1161/JAHA.116.003970 CrossRefPubMedPubMedCentral

69.

Yin J et al (2015) Dysbiosis of gut microbiota with reduced trimethylamine-N-oxide level in patients with large-artery atherosclerotic stroke or transient ischemic attack. JAHA. https://doi.org/10.1161/JAHA.115.002699 CrossRefPubMedPubMedCentral

70.

Mueller DM et al (2015) Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control. Atherosclerosis 243:638–644. https://doi.org/10.1016/j.atherosclerosis.2015.10.091 CrossRefPubMed

71.

McEntyre CJ et al (2015) Variation of betaine, N,N-dimethylglycine, choline, glycerophosphorylcholine, taurine and trimethylamine-N-oxide in the plasma and urine of overweight people with type 2 diabetes over a two-year period. Ann Clin Biochem 52:352–360. https://doi.org/10.1177/0004563214545346 CrossRefPubMed

72.

Kuhn T et al (2017) Intra-individual variation of plasma trimethylamine-N-oxide (TMAO), betaine and choline over 1 year. Clin Chem Lab Med 55:261–268. https://doi.org/10.1515/cclm-2016-0374 CrossRefPubMed

73.

Seldin MM et al (2016) Trimethylamine N‑oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-κB. JAHA. https://doi.org/10.1161/JAHA.115.002767 CrossRefPubMedPubMedCentral

74.

Zhu W, Wang Z, Tang WHW, Hazen SL (2017) Gut microbe-generated trimethylamine N‑oxide from dietary choline is prothrombotic in subjects. Circulation 135:1671–1673. https://doi.org/10.1161/CIRCULATIONAHA.116.025338 CrossRefPubMedPubMedCentral

75.

Chen S et al (2019) Trimethylamine N‑oxide binds and activates PERK to promote metabolic dysfunction. Cell Metab 30:1141–1151.e5. https://doi.org/10.1016/j.cmet.2019.08.021 CrossRefPubMed

76.

Craciun S, Balskus EP (2012) Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc Natl Acad Sci USA 109:21307–21312. https://doi.org/10.1073/pnas.1215689109 CrossRefPubMedPubMedCentral

77.

Martinez-del Campo A et al (2015) Characterization and detection of a widely distributed gene cluster that predicts anaerobic choline utilization by human gut bacteria. mBio. https://doi.org/10.1128/mBio.00042-15 CrossRefPubMedPubMedCentral

78.

Wang Z et al (2015) Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163:1585–1595. https://doi.org/10.1016/j.cell.2015.11.055 CrossRefPubMedPubMedCentral

79.

Roberts AB et al (2018) Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nat Med 24:1407–1417. https://doi.org/10.1038/s41591-018-0128-1 CrossRefPubMedPubMedCentral

80.

Maier L et al (2018) Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. https://doi.org/10.1038/nature25979 CrossRefPubMedPubMedCentral

81.

Imhann F et al (2016) Proton pump inhibitors affect the gut microbiome. Gut 65:740–748. https://doi.org/10.1136/gutjnl-2015-310376 CrossRefPubMed

82.

Wu H et al (2017) Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 23:850–858. https://doi.org/10.1038/nm.4345 CrossRefPubMed

83.

Pryor R et al (2019) Host-microbe-drug-nutrient screen identifies bacterial effectors of metformin therapy. Cell 178:1299–1312.e29. https://doi.org/10.1016/j.cell.2019.08.003 CrossRefPubMedPubMedCentral

84.

Haiser HJ et al (2013) Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341:295–298. https://doi.org/10.1126/science.1235872 CrossRefPubMedPubMedCentral

85.

Skelly AN, Sato Y, Kearney S, Honda K (2019) Mining the microbiota for microbial and metabolite-based immunotherapies. Nat Rev Immunol 19:305–323. https://doi.org/10.1038/s41577-019-0144-5 CrossRefPubMed

86.

Rosshart SP et al (2019) Laboratory mice born to wild mice have natural microbiota and model human immune responses. Science. https://doi.org/10.1126/science.aaw4361 CrossRefPubMedPubMedCentral

87.

Rosshart SP et al (2017) Wild mouse gut microbiota promotes host fitness and improves disease resistance. Cell 171:1015–1028.e13. https://doi.org/10.1016/j.cell.2017.09.016 CrossRefPubMedPubMedCentral

88.

Turnbaugh PJ et al (2009) The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 1:6ra14. https://doi.org/10.1126/scitranslmed.3000322 CrossRefPubMedPubMedCentral

Titel: Darm-Herz-Achse
Wie Darmbakterien kardiovaskuläre Erkrankungen beeinflussen
verfasst von: Hendrik Bartolomaeus
Victoria McParland
Dr. med. Nicola Wilck
Publikationsdatum: 20.02.2020
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 2/2020
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-020-04897-0

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Grundlagen der Angiologie bei peripherer arterieller Verschlusskrankheit (pAVK)

Neue onkologische Therapien und ihre kardiovaskulären Risiken

Inherited primary arrhythmia disorders: cardiac channelopathies and sports activity

Evidenzbasierte Reduktion des kardiovaskulären Risikos bei Diabetes